Pharmaceutical News

RSS

More than 40 plant-based compounds can turn on genes that slow the spread of cancer

More than 40 plant-based compounds can turn on genes that slow the spread of cancer, according to a first-of-its-kind study by a Washington State University researcher.

28 Aug 2012

Nicotinamide may combat antibiotic-resistance staph infections

A new study suggests that nicotinamide, more commonly known as vitamin B3, may be able to combat some of the antibiotic-resistance staph infections that are increasingly common around the world, have killed thousands and can pose a significant threat to public health.

28 Aug 2012

Novartis receives EC approval for Jakavi to treat myelofibrosis

Incyte Corporation today announced that its strategic collaborator, Novartis, received approval from the European Commission for Jakavi (INC424, ruxolitinib), an oral JAK 1 and JAK 2 inhibitor discovered by Incyte, for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

28 Aug 2012

Janssen licenses rights to Depomed's Acuform gastric retentive drug delivery technology

Depomed, Inc. today announced that Janssen Pharmaceuticals, Inc., has licensed rights to Depomed's Acuform gastric retentive drug delivery technology.

28 Aug 2012

FDA approves Gilead’s Stribild to treat HIV-1 infection

The U.S. Food and Drug Administration today approved Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), a new once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection.

28 Aug 2012

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), a complete once-daily single tablet regimen for HIV-1 infection for treatment-naïve adults.

28 Aug 2012

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Merz, Inc. today announced the acquisition of CUVPOSA (glycopyrrolate) oral solution for pediatric chronic severe drooling associated with neurologic conditions such as cerebral palsy.

27 Aug 2012

Tris Pharma joins Perrigo to launch first ever store brand ER liquid cough/cold product

Perrigo Company and Tris Pharma, Inc. today announced the commercial launch of a major new store brand product. The new product is equivalent to Delsym extended–release oral liquid suspension containing dextromethorphan polistirex and will be marketed under major U.S. retailer and wholesalers' store brands or own label brands.

27 Aug 2012

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

The U.S. Food and Drug Administration (FDA) has notified Mallinckrodt, the pharmaceuticals business of Covidien, that it has approved a 32 mg tablet strength of EXALGO (hydromorphone HCI) Extended-Release Tablets (CII) for opioid-tolerant patients with moderate-to-severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

Taiwan approves RBC Life Sciences' Stem-Kine for importation and sale

RBC Life Sciences, Inc. announced today that the Company's stem cell supplement, Stem-Kine, has been approved for importation and sale in Taiwan. Stem-Kine is marketed in Taiwan under the name SK Plus.

27 Aug 2012

FDA approves Mallinckrodt's EXALGO (32 mg) sNDA to manage opioid-related pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) filed by Mallinckrodt Inc., a subsidiary of Covidien plc, for the 32 mg dose strength of EXALGO (hydromorphone HCl) Extended-Release Tablets (CII), for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

XJB-5-131 prevents secondary damage of severe traumatic brain injury

Treatment with an agent that blocks the oxidation of an important component of the mitochondrial membrane prevented the secondary damage of severe traumatic brain injury and preserved function that would otherwise have been impaired, according to a research team from the University of Pittsburgh School of Medicine, Graduate School of Public Health and Department of Chemistry in a report published online today in Nature Neuroscience.

27 Aug 2012

EC grants marketing authorization to Meda's Zyclara for treatment of actinic keratosis

Meda announced today that the European Commission (EC) has granted marketing authorization for Zyclara in the European Union. Zyclara (imiquimod 3.75% cream) is a patented product for the treatment of actinic keratosis.

27 Aug 2012

Genzyme receives Refuse to File letter from FDA for LEMTRADA

Genzyme, a Sanofi company, announced it has received a Refuse to File letter from the U.S. Food and Drug Administration (FDA) in response to the supplemental Biologics License Application (sBLA) for the approval of LEMTRADA (alemtuzumab) as a treatment for relapsing multiple sclerosis.

27 Aug 2012

Despite controversy, WHO not likely to change its stance on misoprostol use

Highlighting a recent report by the Journal of the Royal Society of Medicine about the use of the drug misoprostol to prevent postpartum hemorrhage and the WHO's inclusion of the drug on its Essential Medicine List, Guardian health editor Sarah Boseley writes in this post in her "Global Health Blog," "Seldom has there been a drug that has excited as much controversy as misoprostol."

27 Aug 2012

PEI adjuvant improves effect of vaccines against flu, HIV and herpes

Oxford University scientists have discovered a compound that greatly boosts the effect of vaccines against viruses like flu, HIV and herpes in mice.

26 Aug 2012

Research roundup: Who do patients seek for primary care?; Treating kids with antipsychotics

n order to find out what kind of doctor patients were visiting for primary care service, researchers analyzed the frequency in which patients visited generalists and specialists in 1999 and 2007 by using a nationally representative sample of outpatient visits.

26 Aug 2012

Dominican Republic establishes commission to examine implications of including ART in country health plan

"The Dominican Republic is one step closer to ensuring that all people living with HIV access treatment," UNAIDS reports in an article on its webpage, adding, "The country's National Social Security Council has established a commission to look into the technical, financial and operational implications of including antiretroviral therapy (ART) in the Basic Health Plan."

26 Aug 2012

Novira secures $23M in Series A financing to support antiviral development for HBV, HIV

Novira Therapeutics Inc. today announced it has secured $23 million in Series A financing to support the development of its capsid-targeting antivirals for the treatment of chronic hepatitis B (HBV) and HIV infections.

24 Aug 2012

Religion not a barrier to HIV testing, treatment, study finds

"Preachers who promise divine healing have often been blamed for turning desperate HIV-positive people against their life-prolonging antiretroviral (ARV) medication and risking their health, but recent research suggests that religious beliefs may not be a barrier to treatment after all," IRIN/Plus News reports.

24 Aug 2012

Pharmaceutical News

More than 40 plant-based compounds can turn on genes that slow the spread of cancer

Nicotinamide may combat antibiotic-resistance staph infections

Novartis receives EC approval for Jakavi to treat myelofibrosis

Janssen licenses rights to Depomed's Acuform gastric retentive drug delivery technology

FDA approves Gilead’s Stribild to treat HIV-1 infection

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Tris Pharma joins Perrigo to launch first ever store brand ER liquid cough/cold product

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

Taiwan approves RBC Life Sciences' Stem-Kine for importation and sale

FDA approves Mallinckrodt's EXALGO (32 mg) sNDA to manage opioid-related pain

XJB-5-131 prevents secondary damage of severe traumatic brain injury

EC grants marketing authorization to Meda's Zyclara for treatment of actinic keratosis

Genzyme receives Refuse to File letter from FDA for LEMTRADA

Despite controversy, WHO not likely to change its stance on misoprostol use

PEI adjuvant improves effect of vaccines against flu, HIV and herpes

Research roundup: Who do patients seek for primary care?; Treating kids with antipsychotics

Dominican Republic establishes commission to examine implications of including ART in country health plan

Novira secures $23M in Series A financing to support antiviral development for HBV, HIV

Religion not a barrier to HIV testing, treatment, study finds

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News